Tags : JEWEL Study

Sumitomo Dainippon Reports Results of Lurasidone Hydrochloride (lurasidone) in P-III

Shots:  The P-III JEWEL Study involves assessing lurasidone (40 mg/day) vs PBO @6wks. in 483 patients with Schizophrenia, conducted for regulatory approval in Japan The P-III JEWEL Study results demonstrated the patients treated with Lurasidone responded positively; PANSS (Positive and Negative Syndrome Scale) score (-19.3 vs -12.7); AE (47.0% vs 51.1%); patients discontinued treatment (19.4% […]Read More